Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

  • June 2018 •
  • 225 pages •
  • Report ID: 5780003 •
  • Format: PDF
DISEASE OVERVIEW

Glioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells that support nerve cells. It is characterized by rapid growth and its high potential to invade surrounding tissue. GBM is the most lethal type of brain tumor, with fewer than 10% of patients surviving more than five years after diagnosis. It is considered to be incurable, with nearly 100% of patients experiencing disease relapse after initial treatment.

MARKET SNAPSHOT

Approval of Opdivo is expected to make the largest contribution to market growth over the forecast period.
Temozolomide remains the backbone of therapy across all treatment settings.
Incident cases of glioblastoma are forecast to increase by 23% during 2017–37.
Temodar’s future lies in drug combinations, while Avastin will be impacted by biosimilars and pipeline therapies.
Innovative immunotherapies and gene therapies look to serve critically unmet needs in the glioblastoma market.